CH692199A8 - Composes pyridiques et compositions pharmaceutique - Google Patents

Composes pyridiques et compositions pharmaceutique Download PDF

Info

Publication number
CH692199A8
CH692199A8 CH02364/97A CH236497A CH692199A8 CH 692199 A8 CH692199 A8 CH 692199A8 CH 02364/97 A CH02364/97 A CH 02364/97A CH 236497 A CH236497 A CH 236497A CH 692199 A8 CH692199 A8 CH 692199A8
Authority
CH
Switzerland
Prior art keywords
compounds
pharmaceutical compositions
pyridic
oxydation
dihydropyridines
Prior art date
Application number
CH02364/97A
Other languages
English (en)
Other versions
CH692199A5 (fr
Inventor
Danielle Straumann
Shyam Sunder Dr. Chatterjee
Julio Gomez Alvarez-Builla
Jose Minguez M Ortega
De Casa-Juana Munoz Fau
Original Assignee
Cermol S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cermol S.A. filed Critical Cermol S.A.
Priority to CH02364/97A priority Critical patent/CH692199A8/fr
Priority to PT98945453T priority patent/PT1023267E/pt
Priority to DE69818286T priority patent/DE69818286T2/de
Priority to ES98945453T priority patent/ES2206989T3/es
Priority to JP2000515875A priority patent/JP2001519415A/ja
Priority to EP98945453A priority patent/EP1023267B1/fr
Priority to AU92771/98A priority patent/AU747150B2/en
Priority to US09/529,112 priority patent/US6482841B1/en
Priority to AT98945453T priority patent/ATE250034T1/de
Priority to PCT/IB1998/001555 priority patent/WO1999019302A1/fr
Priority to CA002306789A priority patent/CA2306789A1/fr
Publication of CH692199A5 publication Critical patent/CH692199A5/fr
Publication of CH692199A8 publication Critical patent/CH692199A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CH02364/97A 1997-10-09 1997-10-09 Composes pyridiques et compositions pharmaceutique CH692199A8 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CH02364/97A CH692199A8 (fr) 1997-10-09 1997-10-09 Composes pyridiques et compositions pharmaceutique
PT98945453T PT1023267E (pt) 1997-10-09 1998-10-07 Compostos de piridilo e composicoes farmaceuticas que os contem
DE69818286T DE69818286T2 (de) 1997-10-09 1998-10-07 Pyridylverbindungen und diese enthaltende pharmazeutische zubereitungen
ES98945453T ES2206989T3 (es) 1997-10-09 1998-10-07 Compuestos de piridilo y composiciones farmaceuticas que los contienen.
JP2000515875A JP2001519415A (ja) 1997-10-09 1998-10-07 ピリジル化合物およびこれを含有した薬剤組成物
EP98945453A EP1023267B1 (fr) 1997-10-09 1998-10-07 Composes de pyridyle et compositions pharmaceutiques contenant ces composes
AU92771/98A AU747150B2 (en) 1997-10-09 1998-10-07 Pyridyl compounds and pharmaceutical compositions containing them
US09/529,112 US6482841B1 (en) 1997-10-09 1998-10-07 Pyridyl compounds and pharmaceutical compositions containing them
AT98945453T ATE250034T1 (de) 1997-10-09 1998-10-07 Pyridylverbindungen und diese enthaltende pharmazeutische zubereitungen
PCT/IB1998/001555 WO1999019302A1 (fr) 1997-10-09 1998-10-07 Composes de pyridyle et compositions pharmaceutiques contenant ces composes
CA002306789A CA2306789A1 (fr) 1997-10-09 1998-10-07 Composes de pyridyle et compositions pharmaceutiques contenant ces composes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH02364/97A CH692199A8 (fr) 1997-10-09 1997-10-09 Composes pyridiques et compositions pharmaceutique

Publications (2)

Publication Number Publication Date
CH692199A5 CH692199A5 (fr) 2002-03-15
CH692199A8 true CH692199A8 (fr) 2002-06-14

Family

ID=4232069

Family Applications (1)

Application Number Title Priority Date Filing Date
CH02364/97A CH692199A8 (fr) 1997-10-09 1997-10-09 Composes pyridiques et compositions pharmaceutique

Country Status (11)

Country Link
US (1) US6482841B1 (fr)
EP (1) EP1023267B1 (fr)
JP (1) JP2001519415A (fr)
AT (1) ATE250034T1 (fr)
AU (1) AU747150B2 (fr)
CA (1) CA2306789A1 (fr)
CH (1) CH692199A8 (fr)
DE (1) DE69818286T2 (fr)
ES (1) ES2206989T3 (fr)
PT (1) PT1023267E (fr)
WO (1) WO1999019302A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1162197B1 (fr) * 2000-06-08 2004-05-26 Bayer Chemicals AG Procédé pour la préparation des pyridines par oxidation des dihydropyridines en utilisant methyl nitrite
DE10115945A1 (de) * 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
AU2002368531A1 (en) * 2002-12-30 2004-07-22 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Isolation of dihydropyridine derivative and preparation salts thereof
EP1863457A2 (fr) * 2005-03-15 2007-12-12 Lupin Ltd. Compositions pharmaceutiques d'amlodipine et de benazepril.
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
WO2007048803A1 (fr) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Derives de benzimidazolone utiles pour le traitement des troubles premenstruels et d'autres troubles sexuels chez la femme
EP1991228A1 (fr) * 2006-02-28 2008-11-19 Boehringer Ingelheim International GmbH Traitement ou prevention de la cardiopathie valvulaire par la flibanserine
BRPI0712039A2 (pt) * 2006-05-09 2011-12-20 Boehringer Ingelheim Int uso de flibanserina para o tratamento de distúrbios de desejo sexual pós-menopausa
WO2008000760A1 (fr) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibansérine dans le traitement de l'incontinence urinaire et des maladies associées
EP2043648A1 (fr) * 2006-07-14 2009-04-08 Boehringer Ingelheim International GmbH Utilisation de flibansérine pour le traitement de troubles sexuels chez les femmes
BRPI0716439B8 (pt) 2006-08-14 2021-05-25 Boehringer Ingelheim Int sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
BRPI0716436B8 (pt) * 2006-08-25 2021-05-25 Boehringer Ingelheim Int sistema de liberação controlada e método para fabricação do mesmo
JP5087011B2 (ja) * 2007-01-23 2012-11-28 馨 井上 眼疾患モデル用非ヒト動物
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
WO2017131601A1 (fr) * 2016-01-26 2017-08-03 Ataturk Universitesi Bilimsel Arastirma Projeleri Birimi N3,n6-bis (2- (5-méthoxy-1h-indol-3-yl)éthyl) -2,6-diméthyl-4-(2-nitrophényle)pyridine -3,5-dicarboxamide et son utilisation dans le domaine de la neurotoxicité
CN109020875B (zh) * 2018-08-27 2020-05-22 北京市药品检验所 二氢吡啶类化合物脱氢芳构化方法及在药品检测中的用途
EP3976177A4 (fr) * 2019-05-31 2023-05-31 RDiscovery, LLC Inhibiteurs de formation de complexe drp1-filamine
CN112457242B (zh) * 2020-12-03 2021-11-23 广州隽沐生物科技股份有限公司 一种拉西地平杂质b的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3209276A1 (de) * 1982-03-13 1983-09-15 Bayer Ag, 5090 Leverkusen Arzneimittel mit antihypoxischer und ischaemie-protektiver wirkung
EP0179239A3 (fr) * 1984-09-17 1986-08-13 Sterling Drug Inc. Acide 7-(pyridinyl)-/-alkyl-1,4-dihydro-4-oxo-3-quinoléine carboxylique ayant une activité antibactérienne et sa préparation
US4698350A (en) * 1984-09-17 1987-10-06 Sterling Drug Inc. 1-ethyl-6-fluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarboxylic acid and antibacterial use thereof
US4843085A (en) * 1987-07-01 1989-06-27 Yamanouchi Pharmaceutical Co., Ltd. Pyridine derivatives, process for production thereof and pharmaceutical compositions useful as anti-arhytmics
GB8905526D0 (en) * 1989-03-10 1989-04-19 Fujisawa Pharmaceutical Co N-containing heterocyclic compounds,processes for the preparation thereof and composition comprising the same
DE4200714A1 (de) * 1992-01-14 1993-07-15 Bayer Ag Spezieller 1,4-dihydropyridin-3,5-dicarbonsaeureester, verfahren zu seiner herstellung und seine pharmazeutische verwendung
JP3286645B2 (ja) * 1993-03-26 2002-05-27 メルシャン株式会社 光学活性１，４−ジヒドロピリジン誘導体およびその製造方法
DE4430639A1 (de) * 1994-08-29 1996-03-07 Bayer Ag Verwendung von 5-substituierten Pyridin- und Hexahydrochinolin-3-carbonsäurederivaten
WO1997027177A2 (fr) * 1996-01-29 1997-07-31 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derives de dihydropyridine-, pyridine-, benzopyrane- mono- et triazoloquinazoline, leur preparation, et utilsation comme antagonistes des recepteurs de l'adenosine

Also Published As

Publication number Publication date
DE69818286D1 (de) 2003-10-23
ES2206989T3 (es) 2004-05-16
CA2306789A1 (fr) 1999-04-22
EP1023267B1 (fr) 2003-09-17
DE69818286T2 (de) 2004-07-01
ATE250034T1 (de) 2003-10-15
AU747150B2 (en) 2002-05-09
PT1023267E (pt) 2004-01-30
JP2001519415A (ja) 2001-10-23
AU9277198A (en) 1999-05-03
US6482841B1 (en) 2002-11-19
EP1023267A1 (fr) 2000-08-02
WO1999019302A1 (fr) 1999-04-22
CH692199A5 (fr) 2002-03-15

Similar Documents

Publication Publication Date Title
PT1023267E (pt) Compostos de piridilo e composicoes farmaceuticas que os contem
MD1233C2 (ro) Derivaţi de eritromicină, procedeu de preparare a lor şi compoziţie farmaceutică pe baza acestora
NZ236589A (en) A-nor-steroid-3-carboxylic acid derivatives and pharmaceutical compositions
IL100328A0 (en) Dihydro isoquinoline derivatives,their production and pharmaceutical compositions containing them
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
CA2244785A1 (fr) Pentafluorobenzenesulfonamides et analogues
ATE202337T1 (de) Cyclopropylalkansäurederivate
IL84359A0 (en) Substituted cephalosporin sulfones,their preparation and pharmaceutical compositions containing them
BR9408392A (pt) Derivados de ácidos arilacéticos e sua utilização como fungicidas
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент
HUP9601526A2 (hu) Véralvadásgátló hatású peptidil-arginin-aldehid-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
RU94000064A (ru) Новые 2-циано-3-гидроксипропенамиды, метод их получения и содержащие их фармацевтические композиции
DK0742214T3 (da) I hjerte-kar-systemet aktive, nye seco-D steroider samt farmaceutiske præparater indeholdende sådanne
BG104424A (en) Pseudopolymorphic forms of 2-[2-[4-[bis(4-fluorophenyl) methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride
IE792328L (en) Derivatives of dihydropyrrole and tetrahydropyridine.
ATE229028T1 (de) 9-n-ethenylderivate von 9(s)-erythromycylamin
ATE239017T1 (de) 1,4-dihydropyridin-5-carbonsäureester-derivate und verfahren zu ihrer herstellung
EP0802179A4 (fr) Derives d'ester d'amidinonaphtyle substitues
ATE234320T1 (de) Beta,beta-disubstituierte derivate von 9-deoxo-9a-n-ethenyl-9a-aza-9a-homoerythromycin a
GR3034439T3 (en) 17beta-(2-oxo-tetrahydrofuran-4-yl)-thio-androstane derivatives (17beta-(gamma-butyric acid lactone)-thio derivatives) for the treatment of inflammation and pharmaceutical compositions and a process for the production thereof
ES2080445T3 (es) Derivados de ursano, su preparacion y formulaciones farmaceuticas de los mismos.
FI873145A0 (fi) Nya tetracykliska indolderivat.
SE8505801L (sv) I,4-dihydropyridin-derivat, deras framstellning och farmaceutiska beredningar innehallande dessa
HUP0002727A2 (hu) Eljárás fibrinogén csökkentésére benzotiofénszármazékok felhasználásával
DE69928123D1 (de) Ester von 3-(3,4-dihalogenophenyl)-2,6-dioxopiperidine-3-propionsäure als zwischenprodukte

Legal Events

Date Code Title Description
PK Correction

Free format text: RECTIFICATION DU FASCICULE DU BREVET

PL Patent ceased